ATI RN
ATI Pharmacology
1. A healthcare professional is preparing to administer Butorphanol to a client who has a history of substance use disorder. The healthcare professional should identify which of the following information as true regarding Butorphanol?
- A. Butorphanol has a greater risk of abuse than morphine.
- B. Butorphanol causes a higher incidence of respiratory depression than morphine.
- C. Butorphanol cannot be reversed with an opioid antagonist.
- D. Butorphanol can cause abstinence syndrome in opioid-dependent clients.
Correct answer: D
Rationale: Corrected Rationale: Butorphanol, an opioid agonist/antagonist, can lead to abstinence syndrome in clients who are opioid-dependent. This syndrome may present with symptoms like abdominal pain, fever, and anxiety. It is crucial for healthcare professionals to consider this risk when administering Butorphanol to clients with a history of substance use disorder. Choices A, B, and C are incorrect. Butorphanol is less likely to be abused than morphine, causes less respiratory depression than morphine, and can be reversed with an opioid antagonist.
2. Which of the following drugs has a therapeutic effect that increases cardiac output and slows heart rate?
- A. Heparin
- B. Alprazolam
- C. Digoxin
- D. Levothyroxine
Correct answer: C
Rationale: Digoxin is the correct answer. It is a medication known for its positive inotropic effects, which increase cardiac output, and negative chronotropic effects, which slow the heart rate. These effects are achieved by inhibiting the sodium-potassium ATPase pump in myocardial cells. Therefore, Digoxin is commonly prescribed to manage conditions like heart failure and atrial fibrillation, where enhancing cardiac output and reducing heart rate are beneficial. Choices A, B, and D are incorrect because Heparin is an anticoagulant, Alprazolam is a benzodiazepine used for anxiety disorders, and Levothyroxine is a thyroid hormone replacement drug, none of which have the specified therapeutic effects on cardiac function.
3. What is one therapeutic use for nitroglycerin?
- A. Relief or prevention of anginal attacks
- B. Diuresis and mobilization of excess fluid
- C. Decreasing nausea and vomiting
- D. Relief of anxiety
Correct answer: A
Rationale: Nitroglycerin is primarily used for the relief or prevention of anginal attacks. It works by dilating blood vessels, increasing blood flow and oxygen to the heart muscle, thereby relieving chest pain caused by angina. The medication is not indicated for diuresis, antiemetic effects, or anxiety relief. Therefore, choices B, C, and D are incorrect as they do not reflect the therapeutic use of nitroglycerin.
4. A client is receiving discharge instructions for a new prescription of Prednisone. Which of the following dietary instructions should be included?
- A. Increase your intake of potassium-rich foods.
- B. Increase your intake of dairy products.
- C. Avoid foods high in vitamin K.
- D. Decrease your intake of protein.
Correct answer: A
Rationale: When a client is prescribed Prednisone, there is a risk of potassium depletion due to the medication. Therefore, it is essential to increase the intake of potassium-rich foods such as bananas, oranges, and spinach to help maintain adequate potassium levels in the body and prevent complications associated with low potassium levels. Choice B and D are incorrect as there is no specific need to increase dairy products or decrease protein intake with Prednisone. Choice C is also incorrect as avoiding foods high in vitamin K is more relevant for clients taking anticoagulants like warfarin.
5. A client has been prescribed a calcium channel blocker for angina. The nurse knows this medication should NOT be used with caution in combination with which drug classes?
- A. NSAIDs
- B. Cardiac glycosides
- C. Beta blockers
- D. None of the above
Correct answer: C
Rationale: Calcium channel blockers and beta blockers should be used with caution together because they can both suppress heart function, potentially leading to bradycardia, heart block, or heart failure. NSAIDs and cardiac glycosides do not have significant interactions with calcium channel blockers in the same way, so they are not typically a cause for concern when combined.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access